Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade
Authors
Keywords
Annexin A1, Oral squamous cell carcinoma, Induction chemotherapy
Journal
BMC CANCER
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2013-06-21
DOI
10.1186/1471-2407-13-301
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Decreased Expression of Annexin A1 during the Progression of Cervical Neoplasia
- (2013) LD Wang et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease
- (2013) L.-P. Zhong et al. MOLECULAR CANCER THERAPEUTICS
- Clinical Significance of Annexin A1 Expression in Breast Cancer
- (2012) Cha Kyong Yom et al. Journal of Breast Cancer
- Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma
- (2012) Lai-ping Zhong et al. JOURNAL OF CLINICAL ONCOLOGY
- Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients
- (2012) Rong Biaoxue et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Identification of annexin A1 as a proinvasive and prognostic factor for lung adenocarcinoma
- (2011) Ying-Fu Liu et al. CLINICAL & EXPERIMENTAL METASTASIS
- Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial
- (2011) Jochen H Lorch et al. LANCET ONCOLOGY
- Overexpression of Galectin-1 is negatively correlated with pathologic differentiation grade in oral squamous cell carcinoma
- (2010) Lai-ping Zhong et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Decreased expression of Annexin A1 correlates with pathologic differentiation grade in oral squamous cell carcinoma
- (2010) Lei Zhang et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Annexin A1 expression and its prognostic significance in human breast cancer
- (2010) L. Wang et al. NEOPLASMA
- Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy
- (2009) Suebwong Chuthapisith et al. EUROPEAN JOURNAL OF CANCER
- β-Tubulin-II Expression Strongly Predicts Outcome in Patients Receiving Induction Chemotherapy for Locally Advanced Squamous Carcinoma of the Head and Neck: A Companion Analysis of the TAX 324 Trial
- (2009) Kevin J. Cullen et al. JOURNAL OF CLINICAL ONCOLOGY
- Annexin-I overexpression is associated with tumour progression and independently predicts inferior disease-specific and metastasis-free survival in urinary bladder urothelial carcinoma
- (2009) Chien-Feng Li et al. PATHOLOGY
- Down-regulation of plasma membranous Annexin A1 protein expression in premalignant and malignant lesions of the oral cavity: correlation with epithelial differentiation
- (2008) Hitomi Nomura et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Clinical and Histopathologic Independent Prognostic Factors in Oral Squamous Cell Carcinoma: A Retrospective Study of 334 Cases
- (2008) Paolo G. Arduino et al. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
- Nuclear localization of annexin A1 is a prognostic factor in oral squamous cell carcinoma
- (2008) Chiao-Ying Lin et al. JOURNAL OF SURGICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started